CSNK1E Variant 2: A Potential Drug Target and Biomarker (G1454)

Target Name: CSNK1E

NCBI ID: G1454

CSNK1E

CSNK1E Variant 2: A Potential Drug Target and Biomarker

Introduction

Cancer is a leading cause of morbidity and mortality worldwide, with over 20 million new cases and 5.5 million deaths in 2020, according to the World Health Organization (WHO). The development of new treatments and biomarkers for cancer has become a critical area of 鈥嬧?媟esearch . One of the promising targets in cancer research is the CSNK1E gene, which has been identified as a potential drug target and biomarker for various types of cancer. In this article, we will explore the CSNK1E gene, its potential drug target properties, and its role as a biomarker in cancer diagnosis and treatment.

The CSNK1E gene

The CSNK1E gene is located on chromosome 16p13.2 and encodes for a protein named CSNK1E, which is a non-protein kinase (NPK) that is involved in various cellular processes, including cell signaling, cell adhesion, and DNA damage repair. The CSNK1E The gene has four splice variants, including variant 1 (CSNK1E-1), variant 2 (CSNK1E-2), variant 3 (CSNK1E-3), and variant 4 (CSNK1E-4).

CSNK1E-1 and CSNK1E-4 variants are predominantly expressed in human tissues, including liver, lung, and brain. Oncogenic alterations in the CSNK1E gene have been observed in various types of cancer, including breast, ovarian, and colorectal cancer. These mutations have has been associated with the development of cancer-related traits, such as increased cancer cell proliferation, invasion, and metastasis. Therefore, targeting the CSNK1E gene has become an attractive strategy for cancer therapy.

Drug targeting and biomarker potential

The CSNK1E gene has been identified as a potential drug target due to its involvement in various cellular processes that are critical for cancer growth and progression. Several studies have suggested that inhibition of CSNK1E gene function may be an effective way to treat cancer.

One of the most promising strategies for targeting CSNK1E is the inhibition of its activity by small molecules or antibodies. These approaches have been shown to effectively reduce the activity of CSNK1E, leading to the inhibition of its signaling pathway and the downregulation of cancer cell proliferation.

In addition to its potential as a drug target, the CSNK1E gene has also been identified as a potential biomarker for cancer diagnosis and treatment. The expression of CSNK1E has been observed in various types of cancer, including breast, ovarian, and colorectal cancer. Therefore , the levels of CSNK1E expression in cancer tissues can be used as a biomarker for cancer diagnosis and prognosis.

Recent studies have also shown that the expression of CSNK1E is associated with cancer-related outcomes, such as tumor burden, disease stage, and survival. Therefore, measuring the levels of CSNK1E expression in cancer tissues can also be used as a biomarker for cancer monitoring and evaluating the effectiveness of treatments.

Conclusion

In conclusion, the CSNK1E gene has been identified as a potential drug target and biomarker for various types of cancer. Its tumor suppressor effect and involvement in various cellular processes make it an attractive target for cancer therapy. The inhibition of CSNK1E gene function by small molecules or antibodies may be an effective way to treat cancer. Additionally, the CSNK1E gene has also been identified as a potential biomarker for cancer diagnosis and treatment. Further research is needed to

Protein Name: Casein Kinase 1 Epsilon

The "CSNK1E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSNK1E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets